Full-Time

Founding Fellow

New Indications

Ataraxis.ai

Ataraxis.ai

11-50 employees

AI-powered prognostic test for breast cancer

Compensation Overview

$115k - $255k/yr

New York, NY, USA

In Person

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
LLM
Data Analysis

Get referred to Ataraxis.ai

See people who can refer or advise you

Requirements
  • A PhD or Master of Science degree with a research and publication track record is expected for top candidates.
  • Scientific fluency in clinical studies and translational science, including the ability to learn details about drugs and trials.
  • The ability to explain the significance of the company's work compellingly to physicians and researchers.
  • The ability to form independent views on complex questions with incomplete information, reason from first principles, trust intuition, and update conclusions as new information emerges.
  • Comfort with the modern artificial intelligence stack and use of artificial intelligence tools to increase work speed while avoiding low-quality artificial intelligence output.
  • Relentless drive, initiative, follow-through, and the ability to independently manage projects and priorities.
Responsibilities
  • Lead clinical research expansion into additional cancer types or disease areas beyond breast cancer.
  • Own expansion into a new cancer type from early scientific groundwork through the foundation for launch.
  • Build and manage relationships with clinical leaders, advisors, and research collaborators.
  • Work with data and partnerships teams to secure and shape the resources needed by the models.
  • Partner with engineering and research teams to bring the first models in a new indication to life.

Ataraxis.ai creates precision medicine tools for cancer care using artificial intelligence. Its first product, Ataraxis Breast, is an AI-native prognostic test for breast cancer designed to predict patient outcomes more accurately and help doctors personalize treatment plans. Results are delivered quickly, within one business day, through a physician portal or to clinicians. The company differentiates itself by offering an AI-driven prognostic test that aims to set a new standard in molecular diagnostics rather than relying on traditional methods alone, with a focus on rapid, actionable insights for oncology. The goal is to improve how cancer treatment decisions are made by providing fast, data-driven prognostic information to physicians and healthcare providers.

Company Size

11-50

Company Stage

Series A

Total Funding

$44.8M

Headquarters

New York City, New York

Founded

2023

Get referred to Ataraxis.ai

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • March 2025 Series A raised $20.4 million from AIX Ventures and Founders Fund.
  • April 2026 launch of Ataraxis Breast NEO expands the platform beyond chemotherapy benefit.
  • ASCO 2026 presentations and Unicancer validation signal accelerating clinical credibility through mid-2026.

What critics are saying

  • Exactive adoption remains unproven beyond pilots; reimbursement and workflow integration decide 2026 revenue.
  • Exact predictive claims face scrutiny against Oncotype DX, MammaPrint, and institutional pathology models.
  • A verdict against Ataraxis in the Spine Institute of Idaho dispute creates distraction and appeal risk.

What makes Ataraxis.ai unique

  • Kestrel and Tau combine pathology images with clinical data for individualized cancer decisions.
  • Ataraxis Breast CTX targets chemotherapy benefit, not generic recurrence scoring, in HR-positive breast cancer.
  • Unicancer's 1,100-plus patient phase III datasets give Ataraxis unusually strong clinical-validation access.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

44%

1 year growth

44%

2 year growth

90%
Newzchain
Aug 7th, 2026
Ataraxis AI raises $20M to predict cancer outcomes and reduce unnecessary chemotherapy

Ataraxis AI has raised $20.4 million in a Series A round led by AIX Ventures to commercialise its cancer treatment prediction technology. Thiel Bio, Founders Fund, Floating Point, Bertelsmann, Giant Ventures and Obvious Ventures also participated. The company previously raised $4 million in seed funding. The startup analyses high-resolution images of cancer cells using AI trained on hundreds of millions of images from thousands of patients. According to Ataraxis, its technology is 30% more accurate than current standards for breast cancer care. The funding will support the commercial launch of its first breast cancer test and expansion into other cancer types. Co-founded by Jan Witowski and NYU professor Krzysztof Geras, Ataraxis aims to help predict long-term cancer outcomes and potentially reduce unnecessary chemotherapy treatments.

Business Wire
Mar 30th, 2026
Ataraxis AI launches first predictive test estimating individualised chemotherapy benefit in breast cancer

Ataraxis AI has launched Ataraxis Breast CTX, an AI-powered test that estimates individualised chemotherapy benefit in breast cancer patients. The platform combines digitised pathology slides with clinical data to predict patient-level outcomes with and without adjuvant chemotherapy. The test was developed using multimodal data from over 10,000 breast cancer patients worldwide and validated across observational studies and randomised controlled trials. It has been adopted by top NCI-designated cancer centres and community clinics across the United States. Ataraxis Breast CTX uses the company's Tau causal inference layer to account for treatment selection bias. The platform aims to identify high-risk patients unlikely to benefit from chemotherapy, helping clinicians make more informed treatment decisions and potentially reduce overtreatment. The test is offered through a CLIA-certified laboratory.

Femtech Insider
Mar 14th, 2025
Ataraxis AI Raises $20.4M for Cancer Diagnostics

Ataraxis AI has raised $20 million in Series A funding to advance its AI precision medicine platform, focusing on Ataraxis Breast for breast cancer diagnostics. Led by AIX Ventures, the round included investors like Thiel Bio and Founders Fund. The Kestrel model, central to their platform, is 30% more accurate than current standards. The funding will aid in expanding treatment capabilities and developing new AI models, with plans to launch Ataraxis Breast in the U.S. later this year.

AlleyWatch
Mar 10th, 2025
Ataraxis AI raises $20.4M Series A

Ataraxis, an AI precision medicine company focused on cancer diagnostics, has raised $20 million in Series A funding led by AIX Ventures. Founded by Jan Witowski and Krzysztof Geras in 2022, Ataraxis has now raised a total of $24 million in reported equity funding.

Wow Partners, Inc.
Mar 6th, 2025
Ataraxis AI Raises $20.4M for Cancer Treatment

Ataraxis AI, a New York-based startup, secured $20.4 million in Series A funding led by AIX Ventures, with participation from Thiel Bio, Founders Fund, and others. The company, co-founded by Jan Witowski and Krzysztof Geras, uses AI to predict cancer progression and reduce unnecessary chemotherapy. Their breast cancer diagnosis accuracy is 30% higher than standard methods. The funds will aid in expanding to other cancer types and enhancing technology.